Amneal Pharmaceuticals, Inc. (AMRX) along with Shilpa Medicare Limited, Thursday announced that the U.S. Food and Drug Administration has approved BORUZU, the first ready-to-use version of bortezomib for subcutaneous administration.
The companies expect to launch the bortezomib injection in the second quarter of 2025, which could be used for the treatment of multiple myeloma and mantle cell lymphoma.
"These ready-to-use injectable presentations are important innovations for oncology providers as they reduce the pharmacy preparation steps for clinicians," said Sean McGowan, Vice President, Biosimilars and Branded Oncology.
For comments and feedback contact: editorial@rttnews.com
Health News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.